FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $42.80, for a total transaction of $85,600.00. Following the completion of the sale, the director now directly owns 22,000 shares in the company, valued at $941,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Tuesday, December 12th, Kalevi Kurkijarvi sold 12,000 shares of FibroGen stock. The shares were sold at an average price of $44.45, for a total transaction of $533,400.00.
  • On Friday, November 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $46.65, for a total transaction of $93,300.00.
  • On Tuesday, October 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $52.24, for a total transaction of $104,480.00.

Shares of FibroGen Inc (FGEN) traded up $1.20 during trading on Thursday, hitting $44.55. 484,200 shares of the stock traded hands, compared to its average volume of 627,022. FibroGen Inc has a fifty-two week low of $19.25 and a fifty-two week high of $60.15. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in shares of FibroGen in the 2nd quarter valued at $128,000. Ameritas Investment Partners Inc. raised its position in FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the last quarter. SG Americas Securities LLC raised its position in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 412 shares during the last quarter. Amalgamated Bank purchased a new stake in FibroGen in the 2nd quarter valued at $237,000. Finally, Oppenheimer Asset Management Inc. raised its position in FibroGen by 112.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,336 shares during the last quarter. Institutional investors and hedge funds own 57.37% of the company’s stock.

A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price objective for the company. Finally, Jefferies Group restated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.67.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/kalevi-kurkijarvi-sells-2000-shares-of-fibrogen-inc-fgen-stock/1776367.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.